A new inhalation treatment for lung diseases caused by mucus buildup
Official title: A Novel ENaC Blocker/Osmolyte Inhalation Solution for the Treatment of Muco-Obstructive Lung Diseases
Funded at Parion Sciences, INC. · NIH-10918480 · Data updated 2026-11-12
This study is testing a new inhaler solution that combines two ingredients to help people with lung diseases like COPD, asthma, and cystic fibrosis breathe better by clearing out mucus that blocks their airways.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Parion Sciences, INC. NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project start | May 1, 2024 |
| Project end | April 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $295,700 |
| NIH project number | 1R44HL174235-01 |
| Project ID | NIH-10918480 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with muco-obstructive lung diseases such as COPD, asthma, cystic fibrosis, or primary ciliary dyskinesia.
✕Less likely to help
Patients with lung diseases not primarily associated with mucus obstruction or those who do not respond to inhalation therapies may not benefit from this research.
What this research studies
This research focuses on developing a novel inhalation solution that combines a new ENaC blocker with an osmolyte to help patients suffering from muco-obstructive lung diseases like COPD, asthma, and cystic fibrosis. The approach aims to rehydrate and clear mucus plugs that contribute to airway obstruction, which has been shown to persist in patients for extended periods. By utilizing a combination of laboratory studies and clinical trials, the research seeks to establish a new therapeutic option for improving lung function and quality of life for affected individuals.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option that effectively clears mucus from the lungs, improving breathing and overall health for patients with chronic lung conditions.
How similar studies have gone: Previous research has shown promise with similar therapeutic approaches, particularly in the treatment of primary ciliary dyskinesia, indicating potential for success in this novel application.
Where this research is happening
-
Parion Sciences, INC.
Durham, United States Active
Researchers
- Principal investigator: Donn, Karl H — Parion Sciences, INC.
- Study coordinator: Donn, Karl H
Related research
Other NIH-funded projects on the same topics.
-
Clinical readiness for rare lung diseases (RLDC)
A group at the University of Cincinnati is building a program to speed up care for people with rare lung diseases by tracking patients over time, improving tests and treatments, and sharing information with patients and clinicians.
-
Epithelial cells trigger fibroblast activation in lung fibrosis through CTHRC1-TGFb signaling
A clinician-scientist at Duke is studying how lung lining cells may turn normal fibroblasts into fibrosis-causing cells, aiming to uncover new targets for treatment of diseases like BO and IPF.
-
Molecular origins of chronic lung diseases in the human lung
Researchers are mapping the tiny cell neighborhoods in diseased lungs to find early clues that could protect or restore normal lung function.
-
How lung cells and their surroundings drive fibrosis in interstitial lung diseases
A study to understand how airway cells, surrounding tissue, and their environment contribute to progressive scarring in interstitial lung diseases.
-
Loss of Cilia Maintenance in Acquired and Genetic Lung Diseases
Researchers are studying why tiny hair-like structures in the lungs lose their maintenance and how this affects people with asthma, COPD, and related airway diseases.
-
CMKLR1-targeted imaging to map lung inflammation in ALI and fibrotic lung diseases
A study to test a new PET imaging tool that targets CMKLR1 to visualize lung inflammation and help predict and monitor disease progression in patients with acute lung injury and fibrotic lung diseases.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.